Image description

Enuresis

Epidemiology

  • Up to 10% prevalence among 5 year olds
  • Approximately 1% among individuals 15 years and older
  • At age 3 to 4 years, maturation of function and control over the external urinary sphincter AND control over bladder-sphincter unit so child can voluntary initiate and inhibit micturition occurs.
  • Key point 1: Provide reassurance to families and let the child know how common and normal it may be to still be wetting the bed.
  • Key point 2: The longer enuresis persists, the lower probability of spontaneous resolution (i.e. older children with enuresis requires more attention and treatment)


Definitions:

  • Enuresis - Intermittent incontinence while asleep in a child >= 5 years of age
  • Primary enuresis - nighttime wetting in a child who has not been dry for at least 6 months
  • Secondary enuresis - return of nighttime wetting after a child has been dry for at least 6 months
  • Monosymptomatic enuresis - Enuresis with no other lower urinary tract symptoms (LUTS) and limited to nighttime enuresis
  • Non-monosymptomatic enuresis - Enuresis with other, mainly daytime, LUTS
  • Nocturia - Nighttime awakening to void
  • Nocturnal enuresis - nighttime incontinence


History

  • Day vs nocturnal enuresis
  • # episodes bedwetting per week
  • Fluid intake (especially in the evening or night)
  • Juice, caffeine, or alcohol intake (especially soda, teas, and energy drinks!)
  • Constipation
  • Fecal incontinence - not due to insufficient wiping of the bottom


Red Flag History***

Presence of one or more suggestive for underlying bladder dysfunction (consider sending straight to Urology)

  • Leakages of urine during the day
  • Intermittent or continuous leakage
  • Urinary frequency (>= 8x/day)
  • Sudden and urgent need to urinate
  • Holding maneuvers observed (e.g. Vincent's curtsey - pressing heel into perineum, leg crossing, standing on tiptoes)
  • Straining to urinate
  • Interrupted urinary stream or several voids, one after another
  • History of recurrent urinary tract infections
  • Associated neurologic symptoms


Physical Exam

Goal: 1) Confirm normal anatomy 2) look for anatomic abnormalities 3) look for neurologic abnormalities


Genital Exam

  • Check underwear - signs of fecal incontinence
  • Physical abnormalities (e.g. phimosis, labial adhesions)

Back Exam

  • Spinal dysraphism (e.g. dimple, hemangioma, lipoma, patch of hair, sacral agenesis)
  • Scoliosis (another potential sign of spinal dysraphism)

Neuro Exam

  • Muscle atrophy
  • Abnormal gait
  • Lower extremity weakness

MSK Exam

  • Foot deformities (high arch, hammer toes, clubfoot/equinovarus, limb-length discrepancies)
  • Tight heel cords (can be sign of spasticity)


Labs/Tests

  • Urinalysis (assess for glycosuria or signs of infection)
  • +/- Urine culture


Management

If non-monosymptomatic enuresis and/or signs of LUTS, refer to Urology!


Monosymptomatic enuresis can be treated by a general practitioner using:

1) Treat any coexisting constipation FIRST

2) Restriction of fluid and diuretic intake around bedtime (no fluids after dinner or limit no more than 1 glass before bedtime)

3) Bedwetting alarm

  • Consistence is KEY
  • Trial for 6-8 weeks DAILY

4) Desmopressin acetate

  • Recommended starting dose 0.2 mg PO administered 1 hours prior to bedtime
  • Titrate up to 0.4 mg-0.6 mg daily based upon clinical response (dosage is individualized for each patient)
  • Limit fluid intake to a minimum from 1 hour before administration (no fluids after dinner), and until the next morning, or at least 8 hours after administration
  • Precaution: Hyponatremia from antidiuretic effect of desmopressin which may lead to water intoxication and potential seizures and fatality.
  • Do not administer Desmopressin for patients during acute illnesses due to risk of fluid and/or electrolyte imbalance, or under conditions that increases water intake (exercise or hot weather)


Image description
Image description

Follow-up

If there is non-response to the alarm or desmopressin therapy, the actual diagnosis may be non-monosymptomatic enuresis and non monosymptomatic enuresis. Assess upon re-evaluation. If any suspicion for non-monosymptomatic enuresis, refer to the appropriate specialist.


Constipation is a high risk factor for enuresis and treatment resistance; it should be treated prior to managing enuresis.

Potential Reasons for Treatment Failure


Image description

Differential Reasons for Enuresis in Children


1) Monosymptomatic enuresis

  • Polyuria
  • Arousal disorder (e.g. sleep disorders)
  • Nocturnal detrusor overactivity (e.g. diuretics, caffeine, alcohol)


2) Non-monosymptomatic enuresis (See why you would refer to Urology?)

Functional incontinence

  • Dysfunctional voiding
  • Giggle incontinence
  • vaginal entrapment (e.g. vaginal prolapse)
  • Detrusor overactivity

Neurogenic bladder

  • Spina bifida
  • Tethered cord
  • Sacral malformation
  • Cerebral palsy
  • Spinal cord tumors
  • Imperforate anus
  • Trauma

Anatomic abnormalities

  • Exstrophy epispadias complex
  • Ectopic ureter and ureterocele
  • Cloacal malformations
  • Urethral valve abnormalities
  • Syringocele

Parental Handouts

CHOP Voiding Chart for tracking voiding

  • https://www.chop.edu/sites/default/files/urology-voiding-chart-2.pdf


Information about bedwetting:

  • https://www.healthychildren.org/English/health-issues/conditions/genitourinary-tract/Pages/Nocturnal-Enuresis-in-Teens.aspx?gad_source=1&gad_campaignid=69654055&gbraid=0AAAAADyMpZF-tbkbYisFeuWsGfrYiZ0wn&gclid=CjwKCAjw-J3OBhBuEiwAwqZ_h3wiBjcny9jei8xpQiThC4qnVtMkNUaHkH3-61BdEtIS7KNe3qRKDxoCCbgQAvD_BwE


Information about bedwetting alarms and how to use them:

  • https://www.kidney.org/directions-your-child-when-using-bed-wetting-alarm

References

  1. Jonathan Apostol Guzman, Lane S. Palmer; Nocturnal Enuresis. Pediatr Rev August 2024; 45 (8): 479–481. https://doi.org/10.1542/pir.2023-006166
  2. https://www.ics.org/Publications/ICI_4/files-book/Comite-9.pdf
  3. Aaron P. Bayne, Steven J. Skoog; Nocturnal Enuresis: An Approach to Assessment and Treatment. Pediatr Rev August 2014; 35 (8): 327–335. https://doi.org/10.1542/pir.35-8-327
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021795s006lbl.pdf